Webinar Date/Time: Thu, Sep 12, 2024 11:00 AM EDT
The future of validation is here! The State of Validation is the only annual research report dedicated to the validation industry. Join this webinar to dive deep into the findings with validation industry experts who will offer their unique perspectives on the implications and opportunities revealed in the report.
Register Free: https://www.pharmexec.com/pe_w/advancing-validation
Event Overview:
Explore the latest pharmaceutical validation developments during this panel discussion with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape. Attend to learn:
Key Learning Objectives:
Who Should Attend:
This webinar is a must-attend for validation, quality assurance, and compliance professionals seeking to understand the evolving landscape of their field, gain insights from leading experts, and discover how to leverage these changes for better compliance and enhanced efficiency in their organizations.
Speakers:
Art Gehring
Vice President, Marketing
Kneat Solutions
As vice president of marketing at Kneat Solutions, Art Gehring leads a global team of world class marketers educating the industry on the benefits of digital validation. Prior to joining Kneat in 2023, Gehring was a marketing executive and QMS software leader ETQ, helping organizations enhance and automate manual quality processes. Gehring’s tenure also includes leadership roles at Lotus/IBM, Brainshark, ATG, and Virgin Pulse. He holds an MBA in marketing and BS in economics. Gehring and his family of 5 live in Lexington, Massachusetts.
Adolfo Santana
Partner, Quality and Regulatory Compliance Consulting Services
Barry-Wehmiller Design Group
Adolfo Santana is a life sciences partner in the regulatory compliance practice, with over 30 years of experience in pharmaceutical product technical development, scale up, and commercialization, quality systems design and implementation, and regulatory inspection preparation and compliance remediation. He is a subject matter expert in all stages of process validation and commissioning, qualification, and validation of facilities, utilities, systems, and equipment in pharmaceuticals, biologics, and medical device manufacturing environments. Santana has developed and taught much of Barry-Wehmiller Design Group’s internal training curriculum for the regulatory compliance practice. Prior to joining Barry-Wehmiller Design Group, Santana worked in pharmaceutical formulation development R&D, process development and engineering, and regulatory compliance for Schering Plough Research Institute and GSK. Santana holds a bachelor of science in applied analytical chemistry from the New Jersey Institute of Technology.
Joonleong Ng
Business Director Singapore
dambrose
Joonleong Ng has 15 years of experience across the APAC region with a focus on commissioning, qualification, and validation in the pharmaceutical industry. Throughout the years, Ng has gathered extensive hands-on and management experience. He also possesses in-depth knowledge of regulation and guidelines, project management, change control process, and lean leadership.
Register Free: https://www.pharmexec.com/pe_w/advancing-validation
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.